Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
CCL22 controls immunity by promoting regulatory T cell communication with dendritic cells in lymph nodes.
Rapp M, Wintergerst MWM, Kunz WG, Vetter VK, Knott MML, Lisowski D, Haubner S, Moder S, Thaler R, Eiber S, Meyer B, Röhrle N, Piseddu I, Grassmann S, Layritz P, Kühnemuth B, Stutte S, Bourquin C, von Andrian UH, Endres S, Anz D. Rapp M, et al. Among authors: haubner s. J Exp Med. 2019 May 6;216(5):1170-1181. doi: 10.1084/jem.20170277. Epub 2019 Mar 25. J Exp Med. 2019. PMID: 30910796 Free PMC article.
Suppression of intratumoral CCL22 by type i interferon inhibits migration of regulatory T cells and blocks cancer progression.
Anz D, Rapp M, Eiber S, Koelzer VH, Thaler R, Haubner S, Knott M, Nagel S, Golic M, Wiedemann GM, Bauernfeind F, Wurzenberger C, Hornung V, Scholz C, Mayr D, Rothenfusser S, Endres S, Bourquin C. Anz D, et al. Among authors: haubner s. Cancer Res. 2015 Nov 1;75(21):4483-93. doi: 10.1158/0008-5472.CAN-14-3499. Epub 2015 Oct 2. Cancer Res. 2015. PMID: 26432403 Free article.
Cancer cell-derived IL-1α induces CCL22 and the recruitment of regulatory T cells.
Wiedemann GM, Knott MM, Vetter VK, Rapp M, Haubner S, Fesseler J, Kühnemuth B, Layritz P, Thaler R, Kruger S, Ormanns S, Mayr D, Endres S, Anz D. Wiedemann GM, et al. Among authors: haubner s. Oncoimmunology. 2016 Apr 25;5(9):e1175794. doi: 10.1080/2162402X.2016.1175794. eCollection 2016. Oncoimmunology. 2016. PMID: 27757295 Free PMC article.
Recent developments in immunotherapy of acute myeloid leukemia.
Lichtenegger FS, Krupka C, Haubner S, Köhnke T, Subklewe M. Lichtenegger FS, et al. Among authors: haubner s. J Hematol Oncol. 2017 Jul 25;10(1):142. doi: 10.1186/s13045-017-0505-0. J Hematol Oncol. 2017. PMID: 28743264 Free PMC article. Review.
HLA-independent T cell receptors for targeting tumors with low antigen density.
Mansilla-Soto J, Eyquem J, Haubner S, Hamieh M, Feucht J, Paillon N, Zucchetti AE, Li Z, Sjöstrand M, Lindenbergh PL, Saetersmoen M, Dobrin A, Maurin M, Iyer A, Garcia Angus A, Miele MM, Zhao Z, Giavridis T, van der Stegen SJC, Tamzalit F, Rivière I, Huse M, Hendrickson RC, Hivroz C, Sadelain M. Mansilla-Soto J, et al. Among authors: haubner s. Nat Med. 2022 Feb;28(2):345-352. doi: 10.1038/s41591-021-01621-1. Epub 2022 Jan 13. Nat Med. 2022. PMID: 35027758 Free PMC article.
Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML.
Haubner S, Perna F, Köhnke T, Schmidt C, Berman S, Augsberger C, Schnorfeil FM, Krupka C, Lichtenegger FS, Liu X, Kerbs P, Schneider S, Metzeler KH, Spiekermann K, Hiddemann W, Greif PA, Herold T, Sadelain M, Subklewe M. Haubner S, et al. Leukemia. 2019 Jan;33(1):64-74. doi: 10.1038/s41375-018-0180-3. Epub 2018 Jun 26. Leukemia. 2019. PMID: 29946192 Free PMC article.
Characterization of a Novel FLT3 BiTE Molecule for the Treatment of Acute Myeloid Leukemia.
Brauchle B, Goldstein RL, Karbowski CM, Henn A, Li CM, Bücklein VL, Krupka C, Boyle MC, Koppikar P, Haubner S, Wahl J, Dahlhoff C, Raum T, Rardin MJ, Sastri C, Rock DA, von Bergwelt-Baildon M, Frank B, Metzeler KH, Case R, Friedrich M, Balazs M, Spiekermann K, Coxon A, Subklewe M, Arvedson T. Brauchle B, et al. Among authors: haubner s. Mol Cancer Ther. 2020 Sep;19(9):1875-1888. doi: 10.1158/1535-7163.MCT-19-1093. Epub 2020 Jun 9. Mol Cancer Ther. 2020. PMID: 32518207
Cooperative CAR targeting to selectively eliminate AML and minimize escape.
Haubner S, Mansilla-Soto J, Nataraj S, Kogel F, Chang Q, de Stanchina E, Lopez M, Ng MR, Fraser K, Subklewe M, Park JH, Wang X, Rivière I, Sadelain M. Haubner S, et al. Cancer Cell. 2023 Nov 13;41(11):1871-1891.e6. doi: 10.1016/j.ccell.2023.09.010. Epub 2023 Oct 5. Cancer Cell. 2023. PMID: 37802054 Free article.
12 results